Sign In
Buy REGN
$628.73
+9.78 (+1.58%)
At Close: Jun 04, 2026
Regeneron (REGN) Loses 13% in Three Months: What Lies Ahead?
09:17am, Wednesday, 05'th Jul 2023
Regeneron (REGN) declines 13% in the last three months due to regulatory setback for 8 mg dose strength of aflibercept and competition for lead drug.
Regeneron to Report Second Quarter 2023 Financial and Operating Results and Host Conference Call and Webcast on August 3, 2023
04:01pm, Thursday, 29'th Jun 2023
TARRYTOWN, N.Y., June 29, 2023 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it will report its second quarter 2023 financial and operating results on Thursda
Why Regeneron Pharmaceuticals Stock Dipped This Week
02:04pm, Thursday, 29'th Jun 2023
Regeneron's high-dose version of Eylea was rejected by the FDA this week due to manufacturing issues. Wall Street thinks this setback will delay the drug's approval by no more than three months.
Three-Stock Lunch: REGN, PINS & GNRC
03:29pm, Wednesday, 28'th Jun 2023
Lee Munson, Portfolio Wealth Advisors president and CIO, joins 'Power Lunch' to discuss three stocks: Regeneron, Pinterest and Generac Holdings.
Regeneron drops as US FDA declines to approve higher-dose version of its eye disease treatment
08:51am, Wednesday, 28'th Jun 2023
Regeneron Pharmaceuticals Inc (NASDAQ:REGN) shares plummeted by nearly 9% in after-hours trade on Tuesday after the US Food and Drug Administration (FDA) declined to approve a higher-dose version o
Regeneron (REGN) Gets CRL for Aflibercept 8 mg Drug, Shares Fall
07:36am, Wednesday, 28'th Jun 2023
Regeneron (REGN) receives a completed response letter for the application seeking approval of aflibercept 8 mg for treating several retinopathic indications. The stock falls 9% following the news.
Regeneron shares fall after FDA rejects high-dose eye disease treatment
04:49pm, Tuesday, 27'th Jun 2023
Regeneron said the rejection was "solely due to an ongoing review of inspection findings at a third-party filler."
Regeneron Stock Slumps After FDA Decision Delays Blockbuster Release
04:01pm, Tuesday, 27'th Jun 2023
The Food and Drug Administration rejected its application for approval of a new, higher-dose version of eye disease treatment Eylea.
Regeneron's high-dose Eylea not approved by FDA
03:02pm, Tuesday, 27'th Jun 2023
Regeneron Pharmaceuticals Inc. REGN, -1.34% said Tuesday that the U.S. Food and Drug Administration issued a complete response letter for the biologics license application for a higher-dose version of
US FDA declines to approve Regeneron high-dose Eylea
02:58pm, Tuesday, 27'th Jun 2023
The U.S. Food and Drug Administration on Tuesday declined to approve a higher-dose version of Regeneron Pharmaceuticals' blockbuster treatment Eylea, the company said, marking a blow in the drugmaker'
Regeneron Pharmaceuticals Inc. (REGN) Presents at Goldman Sachs 44th Annual Global Healthcare Conference (Transcript)
02:39pm, Wednesday, 14'th Jun 2023
Regeneron Pharmaceuticals Inc. (NASDAQ:REGN ) Goldman Sachs 44th Annual Global Healthcare Conference June 14, 2023 11:40 AM ET Company Participants Ryan Crowe - VP, IR Bob Landry - EVP & CFO Marion Mc
2 Stocks to Buy No Matter What Happens in June and Beyond
10:00am, Wednesday, 14'th Jun 2023
Regeneron has important regulatory milestones to hit in the next year. Microsoft's diversified business and growth opportunities bode well for its future.
Regeneron: Solid Investment Based On Continued EYLEA Expansion
05:55pm, Tuesday, 13'th Jun 2023
Regeneron Pharmaceuticals, Inc. has potential to receive FDA approval of higher dosing of 8 mg of EYLEA, which has been set with an FDA target action date of June 27, 2023. The additional indication i
Regeneron Pharmaceuticals, Inc. (REGN) Jefferies Global Healthcare Conference (Transcript)
12:43pm, Wednesday, 07'th Jun 2023
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN ) Jefferies Global Healthcare Conference Call June 7, 2023 8:30 AM ET Company Participants Ryan Crowe - Vice President, Investor Relations Bolanle Akinlade
3 Biotech Stocks to Sell in June Before They Crash and Burn
09:11am, Tuesday, 06'th Jun 2023
The biotechnology sector has seen better days. From the heady days of the pandemic when companies were racing to develop a vaccine against Covid-19, the industry is now enduring a hangover as both dem
